How many shares are there in Naturgy?
Abivax S.A. is a clinical-stage biopharmaceutical enterprise headquartered in France, focusing on the discovery, development, and commercialization of therapeutics targeting chronic inflammatory diseases and immune disorders. According to official corporate financial announcements and Euronext Paris disclosures, the enterprise comprises a share capital divided into approximately 79.2 million shares outstanding, supporting its ongoing clinical trial expansions, research funding rounds, and international investor participation.